ScreenerHero
AVXLAnavex Life Sciences Corp.
NAS · US · Healthcare · Biotechnology · anavex.com
3.200USD-5.60%Mkt Cap: 314.24M $P/E: —

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and r…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap314.24M $
Enterprise Value162.65M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-46.38M $
Revenue/Share—
Last Price3.200 USD
Fiscal Year EndSep 2025
MR QuarterMar 2026
Employees34
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0327973006
Valuation
P/E (Trailing)—
P/E (Forward)-5.69
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.38
EPS (TTM)-0.36
EPS (Forward)-0.55
52W Range
2.25512% of range10.40
52W High10.40 USD
52W Low2.255 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-48.89%
ROA-44.67%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.04M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-127.42M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio18.24
Quick Ratio18.18
Book Value/Sh1.313 USD
Cash/Share1.375 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:4
Split DateOct 7, 2015
Analyst Consensus
Rating—
Target (Mean)20.00 USD
Upside (mean)+525.0%
Target Range20.00 USD – 20.00 USD
# Analysts1
Ownership
Shares Out.92.70M
Float89.79M
Insiders1.71%
Institutions40.63%
Short Interest
Short Ratio14.9d
Short % Float16.20%
Short % Out.15.56%
Shares Short14.43M
Short (prev mo.)14.23M
Technical
SMA 502.750 (+16.3%)
SMA 2003.674 (-12.9%)
Beta1.14
S&P 52W Chg18.16%
Avg Vol (30d)954.68K
Avg Vol (10d)664.94K
Technical Indicators
RSI (14)65.9
MACD0.1986
MACD Signal0.1746
MACD Hist.+0.0240
BB Upper3.760 USD
BB Middle2.988 USD
BB Lower2.216 USD
BB Width51.70%
ATR (14)0.1603 USD
Vol Ratio (20d)0.68x